The Nov 2020 Neuroblastoma Parent Global Symposium brought together families affected by neuroblastoma from all around the world with those who work to treat, help, and support them. Presentations from 36 experts from Australia, North America, and Europe shared the latest information on biology, treatments, research, late effects, and psychosocial challenges surrounding a childhood cancer diagnosis. Over 700 parents, medical professionals, charity leaders, and industry representatives from 46 countries were able to view live presentations, panel sessions, and ask questions. 

FEATURED PRESENTATIONS

Naxitamab is the most recent FDA approved drug for the treatment of neuroblastoma. In this video, Dr. Jaume Mora, scientific director of Oncology and Hematology at Sant Joan de Déu Hospital in Barcelona, delves into the history of this drug’s development and its current use in the treatment path for frontline, refractory, and relapse disease.

Dr. Juliet Gray, clinical lead of Pediatric Oncology and Hematology at University Hospital Southampton, reviews Anti-GD2 trials and results and provides insights into the rationale for MiNivAn, a three-pronged approach including a novel combination of immunotherapies currently open in the UK and US.

Content
Sessions
30 plus Experts

2020 STEERING COMMITTEE

The Symposium Steering Committee includes renowned clinicians and researchers spanning Europe, North America and Australia, all volunteering their time, to advise on the scope and content of the program, ensuring a wide range of topics catering to a global audience.

Dr. Daniel Morgenstern, chair of the committee, has previously hosted parent education conferences and is familiar with the specific requirements of parent/guardian-focused events. SKC is very grateful to all members of the Steering Committee for their expertise and guidance in helping to design and deliver this first ever virtual symposium for families affected by neuroblastoma around the world.

Dan
Ami
Steven
Juliet
Michelle
Lucas
Cormac
Navin
Thorsten
Toby

ABOUT THE SYMPOSIUM PARTNERS

skcus
SKCUK
cncf

Solving Kids’ Cancer is not just our name, it’s our mission. We focus on aggressive childhood cancers with low survival rates - because Every Kid Deserves to Grow Up.  

Solving Kids' Cancer helps accelerate new clinical trials of next-generation treatments including immunotherapy,  biomarker-based targeted agents, and new combination therapies through research advocacy, with an understanding of the childhood cancer research landscape and current unmet needs to wisely invest in innovative projects. 

Solving Kids' Cancer UK is a parent-led charity, our vision is for future where no child dies of neuroblastoma or suffers due to its treatment.

As part of our mission, Solving Kids’ Cancer initiates and funds innovative clinical research to provide children with the best and most promising new therapies available closer to home. Our research focus is on clinical trials, seeking to explore new ways of treating neuroblastoma, providing hope and options for children and their families now as well as building on the scientific understanding of this disease for children in the future.

Visit www.solvingkidscancer.org.uk to learn more.

The Children’s Neuroblastoma Cancer Foundation (CNCF) is a non-profit national health organization committed to finding a cure for neuroblastoma through research, education, awareness, and advocacy. The premier source for neuroblastoma information and resources, CNCF initiatives educate the public about a disease dramatically lacking in awareness and funding.

Comprised of families just like yours, we are committed to finding a cure for neuroblastoma through research, education, awareness and advocacy. Visit www.cncfhope.org to find out more about the work of CNCF.